Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE China Biologic Products, Inc.
BEIJING, June 17, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it filed a preliminary prospectus supplement in connection with the commencement of a public offering of shares of its common stock. The Company plans on selling 1,000,000 shares of common stock and certain selling stockholders plan on selling 2,212,500 shares of common stock in the offering. In addition, the Company has granted the underwriters a 30-day option to purchase up to 481,875 additional shares of common stock. The final terms of the offering will depend on market and other conditions at the time of pricing.
The Company intends to use the proceeds that it receives from the offering primarily for general corporate purposes. In addition, if appropriate opportunities arise in the future to acquire or invest in complementary products, technologies or businesses, the Company may use a portion of the net proceeds for such acquisition or investment. The Company will not receive any proceeds from the sale of shares by the selling stockholders.
Morgan Stanley & Co. International plc will act as the sole book-running manager for the offering and Aegis Capital Corp. will act as a co-manager.
The offering will be made pursuant to three shelf registration statements that are already effective with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement and the accompanying prospectuses relating to the offering have been filed with the SEC and are available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectuses, when available, may also be obtained by contacting (i) Morgan Stanley, Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY, 10014, United States of America, or by calling 1-866-718-1649, or by email at firstname.lastname@example.org; or (ii) Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, or by calling 212-813-1010, or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering of these securities will be made only by means of the prospectus supplement and accompanying prospectuses.
About China Biologic
China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company's website www.chinabiologic.com.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements about the proposed offering and the use of the offering proceeds that involve risks and uncertainties. Any forward-looking statements and all other statements that may be made in this news release that are not historical facts are subject to a number of risks and uncertainties, and actual results may differ materially. Specific risks include stock market conditions and our ability to complete the offering on acceptable terms. Please refer to China Biologic filings with the SEC for more information on the risk factors that could cause our actual results to differ. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
China Biologic Products, Inc.
Mr. Ming Yin
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
©2012 PR Newswire. All Rights Reserved.
All content © Copyright 2000 - 2014 WorldNow and KIII. All Rights Reserved.
Users of this site agree to the Terms of Service, Privacy Notice/Your California Privacy Rights, and Ad Choices.